PAREXEL® Access eHub:

Value Through Evidence

Back to Content Hub

Cost effectiveness modelling

Expert in outcomes and evidence, Richard Willke, talks through early-stage economic modeling using pharmacokinetic/ pharmacodynamic (PK/PD) data sets; detailing what has been achieved so far and what further potential it holds.

PAREXEL Interview: Richard Willke, PHD/Pfizer Inc.

Share this: